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Biomaterials that interface with biological systems are used to deliver drugs safely and efficiently; to prevent, detect, and treat disease; to
assist the body as it heals; and to engineer functional tissues outside of the body for organ replacement.The field has evolved beyond selecting
materials that were originally designed for other applications with a primary focus on properties that enabled restoration of function and
mitigation of acute pathology. Biomaterials are now designed rationally with controlled structure and dynamic functionality to integrate
with biological complexity and perform tailored, high-level functions in the body. The transition has been from permissive to promoting
biomaterials that are no longer bioinert but bioactive. This perspective surveys recent developments in the field of polymeric and soft
biomaterials with a specific emphasis on advances in nano- to macroscale control, static to dynamic functionality, and biocomplex materials.
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Biomaterials have been used to augment
tissue function and treat diseases or injuries
for thousands of years—whether selecting
coral or wood for dental implants or fabric
for sutures, implant materials historically
originated by evaluating potential materials
in our surroundings that could be used for
a specific biomedical application. Many times,
this selection process simply involved consid-
eration of the mechanical properties of the
material to restore basic function at the im-
plant site; typically, the materials themselves
were never originally designed to interface
with living tissues. Today, this is no longer
the case, as we now have an advanced tool-
box of synthetic and processing techniques to
rationally create, design, and process mate-
rials with specific properties in mind. These
advancements have come hand in hand with
the integration of theory with experiments,
materials chemistry and biology with engi-
neering, and basic science with application.
As highlighted by the announcement of the
Materials Genome Initiative (1), biomaterial
science is often the stealth technology that
enables breakthroughs in medical devices
that improve health care and save lives.
In fact, the last few decades of research have
led to the emergence of numerous biomaterial
options, along with an increasing sophistica-
tion in the ability to tune and manipulate
complex physical and biological properties.
Such advances in biomaterial science have not
only driven and enabled new medical prod-
ucts, but have served as new tools for in-
vestigation of important biological questions.
The modern biomaterial evolution initiated
with the design of materials—including hard
materials like metals and ceramics—that fo-
cused on outcomes such as mechanical prop-
erties and biocompatibility. This approach led
to the clinical implementation of numerous
materials for biomedical applications, such
as joint replacement, pacemakers, and or-
thodontics. The contemporary age of bio-
materials has advanced with a further focus
on surface functionality, where materials are
now smarter and interface with their envi-
ronment such as by incorporating bioactive
signals to achieve multifunctional design.
These strategies are leading to progress
and improvements in fields ranging from
medical devices, to drug delivery, and to
regenerative medicine.
As one example, vascular stents have been
widely used to open blocked vessels and
restore blood flow to ischemic tissues, and
the design of these stents has significantly
evolved with time. With the development of
Nitinol, a metal alloy of nickel and titanium
with unique shape memory and superelastic
properties, stent design has improved to be
implanted with simpler, minimally-invasive
procedures and to maintain function for
longer periods of time. Next-generation stents
transitioned from passive mechanical devices
to those that actively regulate the biological
interface by integrating biodegradable poly-
mer coatings that locally elute drugs to limit
restenosis and resulting stent failure. These
advances enhanced both the functionality and
efficacy of stent technology for clinical use.
Similarly, the coating of traditional metal
orthopedic implants with bioactive ceramics
improved clinical outcomes by facilitating
osseointegration with bony tissue, and after
the discovery of bone morphogenetic proteins
and their recombinant production, spinal
fusion surgeries benefited from material de-
livery systems that enabled their local pre-
sentation (e.g., INFUSE). Collectively, these
examples demonstrate how material design
can be used to present biological signals that
result in new medical devices and implants
with superior clinical performance. In fact, a
recent report estimated the 2012 global bio-
material market at $44.0 billion and fore-
casted a 15% compounded annual growth
rate between 2012 and 2017, reaching $88.4
billion by 2017 (2).
This perspective focuses primarily on re-
cent developments in polymers and soft
materials, due to the large technological
growth in these systems since the 1990s. This
review is organized to highlight some of the
major advances and modern thinking in bio-
material design, such as the ability to manip-
ulate and control biomaterial properties at
multiple length scales, introduce dynamic
behavior into biomaterials, and capture
biocomplexity and additive functionalities.
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Although some examples address surface
modifications of biomaterials to promote
integration, many of the advances that are
discussed focus on bulk modification of
materials and especially how this influences
the stability and function of encapsulated
molecules and cells. We then conclude with a
forward-looking perspective about the cur-
rent challenges and future directions for
designing the next generation of biomaterials.
From Molecular to Macroscopic
Biomaterials fabrication has evolved across all
size scales—from molecular to macroscopic—
to impart biochemical and biophysical cues
into cell culture platforms for regenerative
medicine, to achieve optimal outcomes in
drug delivery systems, and to improve in vivo
success of medical implants. Our increased
understanding of native tissue architecture
and cell–material interactions, as well as the
development of processing methods and
chemical syntheses has driven the design of
new materials. This section will highlight
advances that have been made in the devel-
opment of a toolbox of synthetic approaches
and fabrication techniques that afford de-
fined structures over a range of biologically
relevant length scales.
From Molecular Organization to Nano-
structure. An increased understanding of
biological structures, with a focus on their
biochemical composition and organization,
has provided insight into the manner by
which molecular structure and chemistry
impart properties into biological systems.
Covalent bonds endow stability (e.g., peptide
bonds), whereas secondary structures confer
material resilience (e.g., resilin, elastin). Peptide
synthesis recombinant protein production
and evolution via phage display have become
invaluable tools to recapitulate similar func-
tionalities in synthetic biomaterial analogs.
Likewise, synthetic approaches (e.g., bio-
orthogonal chemistry) have evolved to enable
the fabrication and functionalization of bio-
materials (e.g., hydrogels) that capture aspects
of native biological structures (3). Collectively,
these techniques have allowed the production
of biomaterials with unique capacities, in-
cluding postmodification of cell culture ma-
trices and to cross-link implantable materials.
Covalent chemistries have dominated the
biomaterials field since its conception.
However, the emergence of supramolecular
chemistry has begun to enhance our under-
standing of biology and capacity for creating
precise, physiologically structured materials.
Nobel Laureate Jean-Marie Lehn insightfully
described supramolecular interactions as
“chemistry beyond the molecule,” (4) because
they enable dynamic macromolecular in-
teractions, as well as the self-organization
necessary to form higher-order structure in
proteins and tissues (5). In the body, supra-
molecular presentation of bio-signals is
exemplified by native extracellular matrix
(ECM) interactions, including receptor–ECM
interactions and heparin-binding proteins. As
such, biomolecule presentation through su-
pramolecular interactions has emerged as a
means of controllable delivery (6), including
through cyclodextrin-mediated sequestration
of small molecules (7) or biomimetic elec-
trostatic protein-matrix interactions (8). Be-
yond the capacity for single molecule–matrix
interactions, the general ECM structure
itself is largely the result of self-assembly
(e.g., fibrillar structure of collagen) and can
be recapitulated, in part, by well-designed
synthetic analogs. These higher-order motifs
are exemplified by self-assembling nano-
structures from peptide amphiphiles (9, 10)
(Fig. 1A), although many alternative means
of biologically inspired supramolecular ma-
terials have been explored, and their impli-
cations toward cell behavior were recently
reviewed (11). In addition to such methods of
self-assembly, nanoparticulate-hydrogel com-
posites are an emergent means of introduc-
ing a wide array of functional behaviors (e.g.,
toughness and thermal or electrical conductiv-
ity). The development and use of such nano-
structured, functional composites has likewise
been a topic of recent review (12).
Building at the Mesoscale. Although self-
assembly processes based on molecular de-
sign have achieved vast success in reca-
pitulating certain aspects of the biological
nanostructure, they face notable challenges.
Among these are relative homogeneity at
larger scales (resulting from thermodynami-
cally controlled assembly) and physiologically
low mechanical properties (owing to the
underlying weak intermolecular forces). To
address these aspects at the nano- and me-
soscale, more active processing methods have
been used to impart defined structure. No-
tably, electrospinning (Fig. 1B) of naturally
derived or synthetic materials has become a
dominant technique to mimic the nano-
fibrous nature of ECM (13). The functional
importance of such microstructural organiza-
tion cannot be discounted, as it enables me-
chanical anisotropy (14) and therefore holds
great promise for formation of biomedical
implants including vascular grafts (15) and
orthopedic connective tissues (16). Toward
formation of porous architectures, other pro-
cesses such as phase separation, leaching,
and directional freezing have also emerged as
versatile methods to process biomaterials that
permit cell and tissue infiltration (17, 18).
The aforementioned methods allow re-
alization of bicontinuous structures at the
nano- and microscale, yet they often display
limited capacity toward generating complex
topographical, mechanical, or biomolecular
presentation. For modulation of these as-
pects, postprocessing of larger scaffolds, such
as by light-mediated reactions (Fig. 1C), has
become instrumental toward spatiotempo-
ral control of biochemical signals on hydro-
gel surfaces or within 3D hydrogels through
either single photon (19) or multiphoton
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Fig. 1. The toolbox of biomaterials processing techniques that enable formation of highly controlled
structures with biochemical and biomechanical features that vary across many size scales, as well as levels
of complexity. These techniques include nanoscale molecular self-assembly, electrospinning, photoli-
thography, geometric self-assembly, and 3D bioprinting. Images reproduced from refs. (A, Left and Center)
10; (A, Right) 9, with permission from AAAS; (B) 112; (C, Left) 113, with permission from Elsevier; (C, Center
and Right) 114; (D, Left) 29, with permission from Macmillan Publishers LTD: Nature Communications;
(D, Right) 27, with permission from AAAS; (E, Top Left and Right) 32; and (E, Bottom) 31.
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(20) irradiation methods. Building on these
advances, selective photopolymerization (21),
addition reactions (22), and degradation
mechanisms (23) have enabled extension of
photopatterning methodologies toward 2D
and 3D presentation of spatially or tempo-
rally varying mechanical properties.
Macroscopic Materials and Their Sub-
assemblies. Ultimately, material design for
biomedical applications must achieve the
capacity for preparation at the tissue scale
with both structure and mechanical proper-
ties suitable for in vivo implantation, prefer-
ably with necessary tissue interfacing to
achieve functionality. Methods employed in
industrial processes, such as injection mold-
ing, have been used to achieve macrostructure
control in biomaterials. These approaches
have enabled recreation of complex struc-
tures at the macroscale with utility toward
application in craniofacial (24) and meniscal
(25) implants. In some cases, the biological
interaction with these materials has been
mediated by biomolecule presentation within
the scaffold, such as sequestration of heparin
and, correspondingly, endogenous BMP-2 to
enhance bone formation (26).
Toward their utility in tissue engineering
applications, material assemblies often re-
quire advanced structural flexibility to re-
capitulate the inhomogeneity of tissue struc-
tures (e.g., spatial presentation of cell and
matrix components). To achieve this, ap-
propriate molecular-, nano-, and meso-scale
signals may be engineered into macroscale
structures through either modification of
bulk hydrogels (top-down) or directed com-
ponent assembly (bottom-up) approaches. A
powerful means of achieving controlled sig-
nal presentation within a homogenous scaf-
fold is photolithography (vide supra), which
embodies the top-down methodology.
Alternatively, two primary means of bottom-
up approaches have emerged to create tissue-
scale structures with nonhomogenous cell
and material compositions. First, pioneering
work by the Whitesides group (27) has
demonstrated means by which materials
may be precast into microgel components
with the desired composition and allowed to
passively self-assemble (Fig. 1D) through hy-
drophobic or capillary forces (28). Owing to
the thermodynamic control of assembly in
these systems, repeatable geometric struc-
tures may be achieved over large length
scales. Toward increasing the complexity of
allowed structures, such tools as field-driven
input have also been used (29). As an alter-
native to this self-assembled approach, tech-
niques like 3D printing (Fig. 1E)—the direct
spatially controlled deposition of materials,
with or without included cells or signals—
have emerged to introduce material structure
at the macroscale. Within only the last few
years, these methods have been extended to
include processes, such as sacrificial printing
to enable perfusion and viability within a
secondarily cast hydrogel (30), layer-by-layer
printing of pluronics or other thermogels
(31), and methods to directly write complex
structures in 3D (32). Looking forward, it is
expected that further inclusion of smaller
scale subassemblies, such as nanostructured
materials and microscale patterning, will aid
in furthering success of these approaches.
From Static to Dynamic
Beyond control of material structure from
the molecular to the macroscale, biomaterials
are also evolving from a traditional, pre-
engineered static design to those that have
dynamic properties. Historically, biomaterials
were intended to provide consistent func-
tions, such as mechanical support (e.g., or-
thopedic implants) or optical properties (e.g.,
contact lenses). This approach has led to the
successful design of numerous clinically used
biomaterials; yet, advances in material design
and polymer chemistry have recently allowed
us to incorporate dynamic features into bio-
materials. This approach ranges from the
design of materials that are degradable, to
eliminate permanent implantation or a sec-
ond surgery for implant retrieval, to those
that have stimuli-responsive properties,
where various chemical and biological
signals can trigger changes in biomaterial
properties or release drugs on-demand.
Incorporating Degradation into Biomat-
erials. Biodegradable materials are those that
transition from an initial, stable structure into
soluble products that can be resorbed and
processed by the body. Examples of such
system have been around for numerous years,
with biodegradable sutures perhaps being the
most common (33). Original resorbable su-
tures consisted of materials such as catgut that
degraded via inherent biological mechanisms,
but these were later engineered from synthetic
and hydrolytically degradable polymers [e.g.,
poly(α-hydroxy esters)]. Other examples of
biodegradable materials used in the clinic in-
clude biodegradable films that limit undesired
adhesions after surgical procedures and de-
gradable fixation devices (e.g., screws and
plates) in orthopedics (34). Important con-
siderations in the design of biodegradable
materials are the rate of degradation and
ensuring that the degradation products are
nontoxic when released.
Biodegradable materials have been applied
widely to biomedical applications to provide
temporal control over material presentation,
including toward the engineering of tissues
or the release of drugs and growth factors
(35). For tissue engineering, the material
may temporarily provide a 3D structure or
“scaffold” for the growing tissue, whereas
degradable materials for drug delivery are
engineered to protect and then release
molecules at desired rates. Hydrogels are
one such class of biomaterials that have
been designed with degradable linkers, for
example, through the introduction of hy-
drolytically or enzymatically cleavable bonds
into the cross-links. Degradable hydrogels have
been synthesized from a range of materials,
including synthetic polymers [e.g., poly(ethylene
glycol) (36), poly(vinyl alcohol) (37), and
poly(propylene fumarates) (38)] and bi-
ologically derived polymers [e.g., hyaluronic
acid (39)]. Toward tissue engineering or
wound healing applications, it is important
that the hydrogel remains intact long enough
for delivered or recruited cells to secrete their
extracellular matrix but not persist too long
as to impede tissue formation. For example,
hydrogels have been optimized for cartilage
tissue engineering by tuning the degradation
rate to control matrix production and dis-
tribution by encapsulated chondrocytes
(40). Likewise, for delivery of entrapped bio-
molecules, hydrogel degradation is primarily
used to alter the diffusion and kinetics of
molecule release, which subsequently controls
their spatiotemporal presentation to local
cells and tissues (41). Often times, these bi-
ological signals are designed to act as mor-
phogens and influence tissue formation and
healing (42).
As a complement to hydrolysis, which often
occurs at pre-engineered rates throughout the
bulk of a material, biomaterials have also been
engineered to degrade via proteases (Fig. 2A),
more similar to how tissues are remodeled in
the body. In pioneering studies by Hubbell
and colleagues, peptides were incorporated
into hydrogel cross-links that cleave through
cell-produced proteases (43, 44), such as
matrix metalloproteinases (MMPs), elastases,
and plasmin (45, 46). With this protease-
mediated degradation and the addition of cell
adhesive signals, these biomimetic hydrogels
were remodeled by cells (47) and could be
tuned for specific applications, such as the
regeneration of bone and vascular structures
(43, 48, 49). In some examples, only growth
factors were embedded into the matrices, and
their release occurred in a “cell-demanded”
fashion (50). This approach can also be
harnessed to control the delivery of mole-
cules to treat diseases where protease activity
is altered, such as rheumatoid arthritis (51),
cancer (52), and after myocardial infarction
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(53); here, the drug release rate and dose
are controlled through a feedback mecha-
nism (i.e., elevated protease activity releases
more drug more quickly). The application of
biologically controlled, adaptive degradation
has been reviewed with regard to hydrogels
and corresponding cell material response
and drug release (54, 55).
Although these examples have focused on
hydrogels, there are many other instances
where degradation is used to control the
dynamic properties of biomaterials. As one
highlight, drug delivery reservoirs have been
incorporated into synthetic devices, where
they are covered by a thin biomaterial film
[e.g., poly(lactic-coglycolic acid) (PLGA)]
(56). Subsequent drug release is mediated
through degradation of the films, where
the timing is dependent on the biodegrad-
able polymer design. Release profiles can be
pulsatile, and efficacy has been shown for the
delivery of chemotherapeutics from device
for targeting tumors (57). Furthermore, stents
have been designed to incorporate various
drugs through biodegradable coatings and
reservoirs (vide supra), where drugs (e.g.,
paclitaxel) are passively released through
polymer degradation at predetermined
concentrations and rates to locally influ-
ence tissue response (e.g., suppress unwanted
scarring or restenosis) (58).
Stimuli-Responsive Biomaterials. Beyond
degradation, biomaterials have been designed
to respond to a range of environmental
stimuli that may involve signals such as
changes in temperature, ionic strength, light
exposure, mechanical stress, magnetic fields,
or pH (59). These stimuli may initiate from
the local biomaterial environment (e.g., after
implantation) or be introduced as an external
“trigger” (i.e., active systems) (Fig. 2B). Bio-
logically responsive mechanisms include en-
zyme catalysis (60), competitive ligand-
receptor binding (61), and nanometer-scale
protein motions (62), where material prop-
erties and therapeutic release are altered
based on the biological environment. Im-
portant examples in this area are the release
of insulin in response to glucose catalysis
(63) or biochemically triggered growth
factor release (64, 65), where the disease
stimuli controls drug delivery. Materials are
also designed so that the presence of spe-
cific proteins can disassemble nanoparticles,
opening up disease-triggered therapeutics
and diagnostics (66). Hydrogels with pH re-
sponsive swelling changes provide advantages
for the oral delivery of therapeutics, where
biomaterials are stable in the stomach and
then release drugs in the intestines (67).
As active systems, biomaterials are being
designed with dynamic properties that in-
troduce temporal signals to cells, toward the
engineering of tissues, the expansion of stem
cells, or to understand complex cellular pro-
cesses. One common dynamic hydrogel sys-
tem includes those fabricated from poly
(N-isopropyl acrylamide), which transition
from a swollen to a collapsed hydrogel when
processed through its lower critical solution
temperature (LCST). Changes in volume,
mechanics, and optical transparency occur
when the material transitions through its
LCST, and these changes have been exploited
to release cells and cell sheets for tissue en-
gineering (68). Another stimulus of particular
interest is light, due to the allowed spatio-
temporal control. Anseth and colleagues in-
troduced light as a trigger for the cleavage of
crosslinks (e.g., containing o-nitro benzyl
groups) in hydrogels (23) for the release of
tethered signals or to probe how dynamic
mechanical properties influence the pheno-
type of valvular interstitial cells (69). Light
has also been used to stiffen materials, where
light introduces new cross-links that can alter
material mechanics at a user-defined time
(70). Beyond light, dynamic properties may
be introduced in ionically cross-linked gels, by
the addition of multivalent cations (71) or in
physically associated DNA-based gels through
the introduction of cDNA (72). All of these
systems have been used to probe cell behavior
in response to dynamic environments.
Actively controlling biomaterials once
implanted in the body is more challenging,
particularly to introduce the stimuli to ma-
terials that are implanted deep within tissues.
Light penetration can be attenuated at many
depths and wavelengths; however, there are
numerous examples where light has been
used to either form materials (73) or alter
Stimuli-Responsive
Shape-Memory Biomaterials
Degradable HydrogelsA
B
C
Fig. 2. Dynamic biomaterials that are based on polymer degradation such as through (A) protease
sensitive peptide crosslinkers to enable cell invasion, (B) stimuli-responsive properties (e.g., local changes
in temperature or pH) for the release of therapeutics, or (C) temperature induced shape-memory changes
such as shown where near-infrared light heats embedded gold nano rods to trigger change from tem-
porary coiled shape to permanent uncoiled shape. Images reproduced from refs. (A) 115 and (C) 116.
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their properties when implanted (74). Ultra-
sound is another trigger that can be intro-
duced to disrupt polymer structure and
release therapeutics (75, 76). As described
with the biodegradable reservoirs above, a
similar system has been developed with
electrochemically activated microchips with
release through the dissolution of a gold
membrane (77). Although this system is
nonpolymeric, it constitutes an important
example of stimuli-responsive properties for
controlled release in implanted materials.
As a subset of responsive biomaterials,
shape-memory materials exhibit changes in
geometry based on triggers such as temper-
ature or light (78, 79). In brief, these materials
are fixed into a temporary shape (usually
under stress) and then transition into a re-
laxed permanent shape following an external
or environmental trigger (Fig. 2C). Such a
dynamic process may lead to the next gen-
eration of minimally invasive implantable
constructs, capable of altering their geometry
once implanted (80). As mentioned above,
shape memory alloys (e.g., Nitinol) were de-
veloped many years ago and have found
commercial application, but the last few de-
cades have led to an increase in the number
of polymeric systems available for biomedical
applications, along with those that under
multiple transitions allow for sequential
geometric changes. These polymers can be
processed from a range of covalently and
physically cross-linked polymers and co-
polymers, including from biodegradable
polymers (78, 79), and have the potential to
be designed for degradation, elution of
drugs, or even signaling to local cells for
improved wound healing.
From Bioinert to Biocomplex
Building on advances in dynamic and re-
sponsive biomaterials, another recent direc-
tion in soft biomaterials is the design of
systems that engage with, respond to, and
integrate into the biological landscape. Such
systems extend beyond passive biological
function (bioinert), and researchers seek to
engineer materials that actively interface with
biologically complex environments (bio-
complex). Discoveries in the biological sci-
ences have revealed how information is
processed and exchanged in the body, expos-
ing new routes toward engineering material–
tissue interactions. For example, the language
of the genetic code presents novel therapeu-
tics; the critical role of the ECM informs tis-
sue engineering and regenerative medicine;
the genetic basis of many diseases (e.g.,
cancer, Marfan syndrome) transforms the
way patients are treated; the communica-
tion networks of the immune system inform
vaccinations and cancer therapy; and the
discovery of the microbiome restructures the
way we think about bacteria.
Toward fueling advances in medicine,
these basic scientific discoveries are essential
in the design of future biomaterials. For ex-
ample, biocomplex materials have the po-
tential to perceive malignant dysfunction and
respond by releasing therapeutics to restore
homeostasis; alternative systems could mimic
critical aspects of the ECM to direct tissue
morphogenesis ex vivo. Often, the biggest
challenge is reducing the biological com-
plexity into essential elements (e.g., rate lim-
iting steps, critical signaling factors) that
enable a synthetic material to perform a de-
sired task. In this manner, biomaterials sci-
entists are leveraging biologic understanding
to design materials that are structurally sim-
ple, yet functionally complex to communicate
with, react to, and synergize with biology to
address clinical needs. This section articulates
the concept of biocomplex materials through
the following examples.
Materials to Deliver Therapeutics: Manip-
ulating Cells from the Inside. Bioinert
micro- and nanocarriers that achieve long
circulation times in the blood have trans-
formed parenteral administration of small-
molecule drugs (81, 82). Potent macro-
molecular biotherapeutics (e.g., antibodies,
recombinant proteins, and nucleic acids)
have been identified that treat a variety of
diseases at the molecular scale; however,
because of their nature, they present unique
challenges for delivery. For example, trans-
lation of these therapeutics requires carriers
that not only circulate for extended periods of
time, but also shield the sensitive molecular
cargo from degradation in the bloodstream,
target specific cells or tissues, and release
cargo at the appropriate site of action. Ad-
ditionally, the design of biocomplex nano-
carriers that address these challenges must be
balanced by the need for structural simplicity
that enables reproducible manufacturing.
Some of the most clinically relevant bio-
therapeutics, whose efficacy hinges on the
design of biocomplex delivery systems, are
nucleic acids (NAs). NA-based therapies,
such as RNA interference [e.g., microRNA
(miRNA) or short interfering RNA (siRNA)]
draw inspiration from native mechanisms
and regulation in the transcription and
translation of genetic material into protein.
RNA interference is a native avenue for
posttranscriptional silencing of gene expres-
sion, whereby miRNA or siRNA selectively
prevent protein synthesis (83). In addition,
exogenous messenger RNA (mRNA) can
induce the production of specific proteins to
up-regulate protein expression (84). Because
NA-based therapies alter intracellular ma-
chinery, their efficiency relies on cytoplasmic
delivery. Moreover, these biomolecules are
particularly sensitive to in vivo conditions,
exhibiting very short half-lives before bio-
chemical decomposition is observed. There-
fore, successful translation requires a delivery
vehicle that offers protection from clear-
ance or nuclease degradation, site-specific
targeting, passage across the cellular mem-
brane, and endosomal or lysosomal escape
(85, 86).
Toward this end, biocomplex polymeric
and lipid-based nanoparticle formulations
have been developed to deliver NAs intrave-
nously, some of which have progressed to
clinical trials (Fig. 3A) (87). Specific advances
have focused on stable nucleic acid lipid
particles (SNALPs) and ionizable lipids that
package NAs and increase transport across
the cell membrane (85, 86). The majority of
NA nanocarriers unintentionally accumulate
in the liver, and to overcome this issue, lipid
structures have been recently developed that
allow for selective passive targeting of heart,
lung, and vascular endothelial tissues (88).
Targeting to tumor cells has been achieved by
functionalizing the surface of delivery vehicles
with ligands that bind specifically to proteins
that are selectively expressed on the surface of
tumor cells (89). A major challenge that re-
mains in the clinical use of NA therapeutics is
their escape from endosomes or lysosomes
into the cytoplasm. Sahay et al. identified
NPC1 as a critical protein in the trafficking of
lipid nanoparticles that can be exploited in the
design of materials that better escape the
endosome (90).
Materials to Present Matrix Cues: Sig-
naling Cells from the Outside. The fields
of tissue engineering and regenerative medi-
cine rely on the proliferation and mainte-
nance of human cells outside of the body.
Seminal culture scaffolds have been designed
to permit cell survival and proliferation but
are inherently passive. Although these bio-
inert scaffolds provided a route to maintain
and culture cells, recent improvements in
scaffold design integrate biofunctional aspects
of the native signaling landscape (91). In
vivo, cells integrate a complex array of signals
from the extracellular environment that
synergize with the genetic code to instruct
cell function, such as proliferation, pheno-
type, and differentiation. As discussed, ECM
cues include both biophysical and bio-
chemical signals that vary on multiple length
and time scales. Toward investigating these
cell–material interactions, the development of
high-throughput screening methodologies is
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essential, as it enables the study of such as-
pects as single-cell processes and rapid crea-
tion of complex microenvironments through
microfabrication (92, 93). Additional signals
are introduced by neighboring cells via cell-
cell contacts or secreted cytokines and
growth factors. Biocomplex 3D culture ma-
trices seek to recapitulate critical ECM cues
and cell–cell signaling events through spa-
tiotemporal control over matrix mechanics
and ligand presentation (94). Toward this
goal, both static and temporally controlled
presentation of adhesive ligands has been
exploited to bias chondrogenic differentiation
of hMSCs (23, 95). In addition, dynamic
control over substrate modulus has been
leveraged to reveal a mechanism of “me-
chanical memory,” bias differentiation of
mesenchymal stem cells, and mature car-
diomyocytes (21, 96–98). To better un-
derstand these complex multiscale signaling
processes, approaches such as “organs-on-a-
chip” have emerged and become a means of
rapidly studying processes such as tissue
growth and drug development (99); however,
these fabrication methods have largely relied
on a limited set of materials used for soft
lithography and have yet to leverage bio-
complex materials to their full potential.
In another approach to communicate with
cells, researchers have developed biocomplex
materials that exploit the language of the
immune system to treat and detect disease
(Fig. 3B) (100). These strategies use an un-
derstanding of how the immune systems
senses a foreign substance, arms itself for
attack, and carries out the attack. Mooney
and coworkers demonstrated implantable
devices that interact with the immune system
to suppress tumor growth (100); specifically,
chemotactic factors were released locally to
recruit dendritic cells, which were then acti-
vated by local presentation of tumor antigens,
which then instructed the immune system to
target cancer cells. Further, a suite of syn-
thetic vaccines have been developed similarly
that communicate with immune cells to in-
crease immunogenicity and, ultimately, vac-
cine efficacy (101).
Materials for Tissue Integration: Coordi-
nating a Series of Multicellular Events.
Beyond intracellular and extracellular signal-
ing, biocomplex materials have been de-
signed to orchestrate multicellular events.
For example, Miller et al. used 3D printing
of sacrificial sugar networks embedded
within hydrogels to fabricate vascularized
neo-tissues (30). Culver et al. used laser
writing of adhesive peptides to instruct
multicellular organization for the fabrica-
tion of vascular networks within hydrogels
(102). Further, gradient biomaterials that
present biochemical ligands in a spatially
defined fashion have been used to re-
capitulate osteochondral and osteotendi-
nous interfaces (103, 104).
Despite these in vitro advances, a major
hurdle in the clinical utility of implantable
biomaterials (including joint replacements,
smart drug delivery materials, and cell car-
riers) is nonspecific protein adsorption and
the accompanying foreign body response
(FBR) (105). No implanted material is truly
bioinert; proteins rapidly adsorb to the sur-
face of biomaterials in the body with random
orientations and configurations (105, 106).
Early, this proteinaceous layer facilitates
neutrophil adhesion and activation (105,
106). With time, macrophages fuse to form
foreign body giant cells that attack the im-
plant surface while recruiting fibroblasts,
which deposit ECM and form a dense, fi-
brotic capsule that isolates the implant from
the surrounding tissue (107). As a more
clear picture of implant rejection has de-
veloped, the community has begun to pre-
sent an array of biocomplex materials that
mitigate the FBR and assist integration with
resident tissue. For example, Jiang and col-
leagues developed Zwitterionic hydrogels
that demonstrate ultra-low protein fouling
(108), and the surface chemistry and nano-
topography of implant surfaces have been
designed to limit macrophage activation
(105). Ratner and colleagues further showed
that implant porosity can be exploited to
tune the FBR and tissue integration (109).
Although these advances demonstrate that
biocomplex materials can assist in the or-
ganization of multiscale tissues, clinical trans-
lation remains hindered by an incomplete
understanding of which critical signals to
present and integrate within biocomplex
scaffolds.
Moving into the Future
There are thousands of different types of
medical devices, diagnostic kits, and phar-
maceutical formulations that exist today as
a result of advances in biomaterial science
and engineering. The polymers and soft bio-
materials used are diverse in their origin,
classification, and properties, and many
products integrate multiple components that
are carefully selected for their performance
and function. However, as we look toward
the future, the design of soft biomaterials
is unifying around concepts that include hier-
archy, complexity, dynamics and adaptation,
Materials to signal cells externally
Immune activating material
Tumor
Immature dendritic cell
Activated dendritic cell
Cytokine
Antigen
Materials to direct cells internally
ECM
Blood vessel
Targeted cell
A
B
Fig. 3. Biocomplex biomaterials interact with and direct cells both internally and externally. For example,
advanced drug delivery vehicles (A) introduce exogenous nucleic acid content to up- or down-regulate
protein expression by transporting sensitive biomolecules through the circulation, actively targeting specific
cells, and releasing the therapeutics into the cytoplasm (86). In addition, biocomplex materials are designed
to present external signals to cells (B), either those that are delivered with the matrix or those that are
recruited exogenously. These biomaterial niches can be loaded with multiple cues, presented in concert or
sequentially, to communicate with, recruit or signal to cells locally. For example, immune activatingmaterials
cooperate with native biological signaling to recruit naïve immune cells to a site in the body, activate them
with target antigens, and equip them to target specific cells or tissues, such as malignant tumor cells (100).
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and healing (110). To realize this potential,
better experimental methods and modeling
tools are needed so that we can understand
how to synthesize and engineer advanced
biomaterials systems. Although modern chem-
istry allows the synthesis of polymers with
controlled molecular weights, defined se-
quences, and integrated biological function-
ality, biomaterial systems depend on how
these structural elements assemble and in-
teract at complex biological interfaces, as this
hierarchy ultimately dictates performance
and function.
The biomaterials that are native to our
body (e.g., the ECM) are profound in their
ability to remodel, adapt, and store and re-
trieve information; this is critical during
processes such as development, growth, and
wound healing. Although biomaterials do not
need to mimic all aspects of the complexities
of a living organism (111), understanding the
fundamentals of these processes unlocks fu-
ture opportunities in rational design of bio-
materials. Contemporary research topics
include the development of healable mate-
rials, drug delivery systems that interact with
and deliver their contents in response to
signals from cells, active materials that pro-
mote healing of tissues that could not oth-
erwise occur, medical devices that integrate
seamlessly with tissues at the implant site,
and stealth nanosystems that serve as senti-
nels to monitor and treat disease. Many of
these developments occur and will continue
to revolve around multidisciplinary institutes
and environments that eliminate barriers and
bring together chemists, biologists, engineers,
and clinicians that can bridge the academic-
industrial divide and engage researchers on
a global scale.
Key to all of these advances will be syn-
thetic tools that allow control of biomaterials
from the molecular to the macro, for pat-
terning and dynamically revealing biological
functionalities, and for engineering bio-
complex materials with enhanced properties,
desired stability, and loaded with the bi-
ological signals delivered in the right context,
locality, and time. Importantly, all of this
must be achieved in a manner that allows
manufacturing at large scales and overcomes
any regulatory challenges with the translation
of new materials. Biological complexity de-
mands better tools to characterize changes in
material properties in situ, from molecular
level features of degradation to structural
changes and functional properties. The body
is a dynamic environment, so biomaterials
constantly experience changes that alter per-
formance, and this highlights the profound
need for methods to allow tracking of
biomaterials in physiologically complex
niches and/or improved in vitro assays
that allow better prediction of in vivo
performance. Finally, to facilitate the dis-
covery process, methods to screen and
model the broad and diverse experimental
space is critical. Clearly, rational material
design will remain an important and lead-
ing approach of the community, but com-
binatorial and high-throughput strategies
that are complemented by biological as-
says and analyses will allow mining of huge
datasets to evolve new hypotheses for im-
proved biomaterial design.
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